Heather M O Hagan


Affiliation: Indiana University
Country: USA


  1. Pulliam N, Tang J, Wang W, Fang F, Sood R, O Hagan H, et al. Poly-ADP-Ribosylation of Estrogen Receptor-Alpha by PARP1 Mediates Antiestrogen Resistance in Human Breast Cancer Cells. Cancers (Basel). 2019;11: pubmed publisher
    ..These results correlate ERα PARylation with tamoxifen resistance and indicate a novel mechanism-based approach to overcome tamoxifen resistance in ER+ breast cancer. ..
  2. Savant S, Sriramkumar S, O Hagan H. The Role of Inflammation and Inflammatory Mediators in the Development, Progression, Metastasis, and Chemoresistance of Epithelial Ovarian Cancer. Cancers (Basel). 2018;10: pubmed publisher
    ..In this review we will discuss the roles inflammation and inflammatory mediators play in the development, progression, metastasis, and chemoresistance of EOC. ..
  3. Ding N, Bonham E, Hannon B, Amick T, Baylin S, O Hagan H. Mismatch repair proteins recruit DNA methyltransferase 1 to sites of oxidative DNA damage. J Mol Cell Biol. 2016;8:244-54 pubmed publisher
    ..This study uniquely brings together several factors that are known to contribute to colon cancer, namely inflammation, mismatch repair proteins, and epigenetic changes. ..
  4. Maiuri A, O Hagan H. Interplay Between Inflammation and Epigenetic Changes in Cancer. Prog Mol Biol Transl Sci. 2016;144:69-117 pubmed publisher
    ..This chapter will detail the interactions between inflammation and epigenetics in tumor initiation, promotion, and immune evasion and how these connections are being leveraged in cancer prevention and treatment. ..
  5. Maiuri A, Peng M, Podicheti R, Sriramkumar S, Kamplain C, Rusch D, et al. Mismatch Repair Proteins Initiate Epigenetic Alterations during Inflammation-Driven Tumorigenesis. Cancer Res. 2017;77:3467-3478 pubmed publisher
    ..Understanding such mechanisms will inform development of pharmacotherapies to reduce carcinogenesis. Cancer Res; 77(13); 3467-78. ©2017 AACR. ..